dovepress.com
Cure8 news brief
Why This Matters
HLH is a rare but life‑threatening complication that can be triggered by herpesvirus infection in immunosuppressed IBD patients. Awareness may speed diagnosis and treatment for symptomatic patients on therapies like JAK inhibitors.
Who Should Pay Attention
Adult patients with Crohn’s disease on immunosuppressants (especially JAK inhibitors), clinicians treating IBD, and hospital teams managing unexplained cytopenias and hyperinflammation.
Study Snapshot
Story typeResearch paper
Evidence typeCase report
Source depthFull source text
What To Know
This is a published case report describing a 27-year-old man with longstanding, refractory Crohn’s disease who developed HSV‑1–triggered secondary hemophagocytic lymphohistiocytosis (HLH) while receiving the JAK1 inhibitor upadacitinib.
The diagnosis was supported by pancytopenia, very high ferritin, hypofibrinogenemia, bone marrow hemophagocytosis, and metagenomic sequencing positive for HSV‑1. Upadacitinib was stopped and the patient received acyclovir, ruxolitinib, and dexamethasone with clinical improvement.
The report emphasizes that patients with IBD—especially those on immunosuppression such as JAK inhibitors—may be at increased risk of severe herpesvirus infections that can trigger HLH, a life‑threatening hyperinflammatory syndrome. The treating team selected ruxolitinib over etoposide because of the patient’s cytopenias and liver dysfunction.
Keep In Mind
Single case report from a peer‑reviewed journal; does not establish frequency or causality. Management reflected individualized clinical judgment in the setting of severe cytopenias and hepatic injury.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationdovepress.com
Indexed viaGoogle News
Source typeWeb article
PublishedJul 30, 2026, 9:31 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Visceral Leishmaniasis-Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn's Disease in Therapy With Anti-TNFα: A Challenging Diagnostic Case Report.
HLH is a rare but serious complication in immunosuppressed IBD patients; visceral leishmaniasis can trigger HLH and may be overlooked outside endemic areas. Early bone marrow assessment can speed diagnosis and treatment.
Visceral Leishmaniasis–Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn’s Disease in Therapy With Anti‐TNFα: A Challenging Diagnostic Case Report
People with Crohn’s disease on anti‑TNF biologics can rarely develop severe infections that trigger life‑threatening hyperinflammatory syndromes like HLH. Early recognition and bone marrow testing can identify treatable...
Adalimumab induced psoriasis in Crohn's disease and treatment with ustekinumab: case ...
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Adalimumab. The original article is from frontiersin.org.